



## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/759,037	01/20/2004	Yosef Shaul	27169	7306	
7590 06/29/2004  G.E. EHRLICH (1995) LTD. c/o ANTHONY CASTORINA SUITE 207 2001 JEFFERSON DAVIS HIGHWAY			EXAM	EXAMINER	
			HILL, MY	HILL, MYRON G	
			ART UNIT	PAPER NUMBER	
			1648		
ARLINGTON,	VA 22202		DATE MAILED: 06/29/2004	DATE MAILED: 06/29/2004	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
	10/759,037	SHAUL ET AL.			
Office Action Summary	Examiner	Art Unit			
	Myron G. Hill	1648			
The MAILING DATE of this communication app Period for Reply	pears on the cover sheet with the c	orrespondence address			
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply If NO period for reply is specified above, the maximum statutory period w Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply be ting within the statutory minimum of thirty (30) day will apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONE	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).			
Status					
Responsive to communication(s) filed on <u>20 Ja</u> This action is <b>FINAL</b> . 2b) ☐ This     Since this application is in condition for allowar closed in accordance with the practice under E	action is non-final. nce except for formal matters, pro				
Disposition of Claims					
4) ⊠ Claim(s) 1-8 is/are pending in the application. 4a) Of the above claim(s) is/are withdray 5) □ Claim(s) is/are allowed. 6) □ Claim(s) is/are rejected. 7) □ Claim(s) is/are objected to. 8) ⊠ Claim(s) 1-8 are subject to restriction and/or e  Application Papers 9) □ The specification is objected to by the Examine	election requirement.				
10) The drawing(s) filed on is/are: a) □ accepted or b) □ objected to by the Examiner.					
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.					
Priority under 35 U.S.C. § 119					
<ul> <li>12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority documents</li> <li>2. Certified copies of the priority documents</li> <li>3. Copies of the certified copies of the priority application from the International Bureau</li> <li>* See the attached detailed Office action for a list</li> </ul>	s have been received. s have been received in Applicati rity documents have been receive u (PCT Rule 17.2(a)).	on No ed in this National Stage			
Attachment(s)  1) Notice of References Cited (PTO-892)  2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)	4)  Interview Summary Paper No(s)/Mail D 5)  Notice of Informal F 6)  Other:				
Paper No(s)/Mail Date 6) [_] Other:					

Application/Control Number: 10/759,037

Art Unit: 1648

## **DETAILED ACTION**

## Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

Claims 1- 8 are drawn to a method of inhibiting HBV attachment by exposing the a hepatic cell to a urine derived protein; claims 1 and 2 are generic.

Claims 3- 8 require a specific SEQ ID#.

Applicant must elect one sequence from those recited in the claims for examination: SEQ ID#s 1, 3- 5, and encoded by a nucleotide that is hybridizable with SEQ ID# 3.

The use of each different sequence in the method is a different invention.

The inventions are distinct, each from the other because of the following reasons:

The claims of Group I are drawn to multiple sequences. Each of the different sequences are independent and distinct inventions because no common structural or functional properties are shared. Accordingly, these sequences are each subject to restriction under 35 U.S.C. 121. Regardless of the Group elected, **Applicant is additionally required to elected a single sequence, which if determined to be patentable, would also be patentably distinct from other sequences.** This requirement is made under 1192 O.G. 68 Notice (November 19, 1996), as examination of more than one sequence in one application would result in an undue burden on the PTO. Failure to elect a specific sequence will be considered to be a non-responsive reply. This is not a species election.

Application/Control Number: 10/759,037

Art Unit: 1648

Because these inventions are distinct for the reasons given above and the search required for one sequence does not overlap with the search for other sequences, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Myron G. Hill whose telephone number is 571-272-0901. The examiner can normally be reached on 9am-6pm Mon-Fri.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James Housel can be reached on 571-272-0902. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Myron G. Hill Patent Examiner 22 June 2004

JEFFREY STUCKER
PRIMARY EXAMINER